AR and Familial prostate cancer: Chen et al (2004) showed, using microarray-based profiling of isogenic prostate cancer xenografts, that increases in AR mRNA were the only changes consistently associated with development of resistance to antiandrogen therapy, providing a strong rationale for targeting the downregulation of androgen receptor (AR) activity in the treatment of advanced prostate cancer.